M & As this week: Pfizer, KDB Capital

Pfizer has acquired 50% stake in IGNITE Immunotherapy. Pursuant to the acquisition, Pfizer will hold 50% equity investment in IGNITE and be responsible for providing research and development funding for three years.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news